Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer von Miller, K, Moul, J W, Gleave, M, Fizazi, K, Nelson, J B, Morris, T, Nathan, F E, McIntosh, S, Pemberton, K, Higano, C S

Volltext

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial von Borghaei, H, O'Byrne, K J, Paz-Ares, L, Ciuleanu, T-E, Yu, X, Pluzanski, A, Nagrial, A, Havel, L, Kowalyszyn, R D, Valette, C A, Brahmer, J R, Reck, M, Ramalingam, S S, Zhang, L, Ntambwe, I, Rabindran, S K, Nathan, F E, Balli, D, Wu, Y-L

Volltext

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients von O’Byrne, K.J., Lee, K.H., Kim, S.-W., Park, K., Nishio, M., Sakai, H., Ohe, Y., Fukuhara, T., Kang, J.-H., Daga, H., Yu, C.-J., Hotta, K., Tanaka, H., Takeda, M., Yokoyama, T., Nathan, F.E., Lee, J.-S.

Volltext

The management of the shoulder skin microbiome (Cutibacterium acnes) in the context of shoulder surgery: a review of the current literature von Moore, Nathan FE, Batten, Timothy J, Hutton, Christopher EJ, White, William James, Smith, Christopher D

Volltext

Paclitaxel and tamoxifen : An active regimen for patients with metastatic melanoma von NATHAN, F. E, BERD, D, SATO, T, MASTRANGELO, M. J

Volltext

Protracted survival after resection of metastatic uveal melanoma von Aoyama, Takekazu, Mastrangelo, Michael J., Berd, David, Nathan, Faith E., Shields, Carol L., Shields, Jerry A., Rosato, Ernest L., Rosato, Francis E., Sato, Takami

Volltext

Universal aspects of cohesion von Lehman, Susan Y., Christman, Lilianna E., Jacobs, D. T., Johnson, Nathan S. D. E. F., Palchoudhuri, Paroma, Tieman, Catherine E., Vajpeyi, Avi, Wainwright, Elliot R., Walker, Justine E., Wilson, Ian S., LeBlanc, Michael, McFaul, Louis W., Uhl, Jonathan T., Dahmen, Karin A.

Volltext

Plasma thrombospondin levels in patients with gynecologic malignancies von Nathan, Faith E., Hernandez, Enrique, Dunton, Charles J., Treat, Joseph, Switalska, Hanna I., Joseph, Rosaline R., Tuszynski, George P.

Volltext

LBA4_PRNivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): Chec... von Peters, S, Ramalingam, S S, Paz-Ares, L, Bernabe Caro, R, Zurawski, B, Kim, S-W, Alexandru, A, Lupinacci, L, de la Mora Jimenez, E, Sakai, H, Albert, I, Vergnenegre, A, Reck, M, Borghaei, H, Brahmer, J R, O’Byrne, K J, Geese, W J, Bhagavatheeswaran, P, Nathan, F E, Hellmann, M D

Volltext

Metatarsal fracture management von Moore, Nathan FE

Volltext

Detection of metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic castration-resistant prosta... von Yu, E. Y., Nathan, F. E., Higano, C. S.

Volltext

Role of detection of metastatic disease as a leading cause of screening failure in an ongoing phase III trial of zibotentan versus placebo in patients with nonmetastatic castration... von Yu, E. Y., Nathan, F. E., Higano, C. S.

Volltext

Treatment patterns by oncologists and urologists for castration-resistant prostate cancer (CRPC) von Alemayehu, B., Engel-Nitz, N. M., Nathan, F. E.

Volltext

Anti-Baka Neonatal Alloimmune Thrombocytopenia: Possible Prevention by Intravenous Immunoglobulin von Nathan, F. E., Herman, J. H., Keashen-Schnell, M., McFarland, J. C., Besa, E. C., Hadley, C., Catalano, P. M.

Volltext

Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessm... von Trump, D. L., Payne, H., Miller, K., De Bono, J. S., Stephenson, J., Burris, H. A., Nathan, F. E., Taboada, M., Morris, T., Hübner, A.

Volltext

Systemic therapy in melanoma von Nathan, Faith E., Mastrangelo, Michael J.

Volltext

GM-CSF and Accelerated Hemolysis von Nathan, F E, Besa, E C

Volltext

Phase I study of the effects of renal impairment on the pharmacokinetic (PK) and safety of satraplatin in patients (Pts) with refractory non-hematologic cancer von Hong, D. S., Galsky, M., Chiorean, E., Mulkerian, D., Greene, D., Nathan, F. E., Petrone, M., Camacho, L. H.

Volltext

Phase I study of the effects of hepatic impairment on the pharmacokinetic (PK) and safety of satraplatin in patients with refractory non-hematologic cancer von Setlik, R. F., Preston, G., Jones, C. B., Sarantopoulos, J., Dufresne, T., Petrone, M. E., Nathan, F. E., Greene, D., Anthony, T., Takemoto, C.

Volltext

Satraplatin: A new treatment option for patients with hormone refractory prostate cancer von Nathan, F. E., Sternberg, C., Sartor, O., Petrylak, D., Witjes, F., Wosikowski, K., Petrone, M. E., Rozencweig, M.

Volltext